NHS agreement on population health management approach using PCSK9 siRNA therapy
The National Health Service (NHS) in the UK has made an agreement on a population health management approach to address increased LDL-c in eligible patients with ASCVD using the PCSK9 siRNA inclisiran. This agreement follows the recommendations from NICE for use of inclisiran in primary care for treatment of patients who have persistently elevated LDL-c levels (≥2.6 mmol/L despite maximally tolerated statins with or without ezetimibe) and a history of certain CV events (ACS, coronary or other arterial revascularization procedures, CHD, ischemic stroke or PAD).
The NICE recommendation in its turn was based on results from the ORION clinical program, including ORION-9, ORION-10 and ORION-11. In these trial, the safety, efficacy and tolerability of inclisiran in reducing LDL-c levels were assessed.
Inclisiran is approved in the EU for use in adults with primary hypercholesterolemia or mixed dyslipidemia, as an adjunct to diet.
“This population health management approach is potentially game-changing, seeking to improve a nation’s health by proactively identifying individuals ‘at highest risk’ and introducing effective solutions that will improve their future health state. This represents a significant advance in patient care through effective lipid management,” said Prof Kausik Ray (London, UK).